Gene Therapy Casgevy denied as duplicate or overlapping therapy by Humana?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Humana typically requires
Humana's specific coverage criteria for gene therapy casgevy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Humana angle on Gene Therapy Casgevy
## Why Humana Denied Casgevy (Exagamglogene Autotemcel) as Duplicate Therapy
Casgevy is a one-time gene-editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia. A duplicate-therapy denial in this context is unusual and warrants immediate scrutiny — because Casgevy operates through a mechanism (CRISPR-based genomic editing of BCL11A) that is categorically different from any other disease-modifying treatment in either condition.
Humana may issue this denial if another disease-modifying therapy (such as hydroxyurea, voxelotor, crizanlizumab, or luspatercept) is active in your current regimen. However, concurrent use of a supportive or disease-modifying agent does not make Casgevy a duplicate — the treatments work at entirely different levels of disease biology. This is a strong factual basis for appeal.
## Your Federal Appeal Rights
- Internal appeal (ACA §2719 / ERISA §503): You are entitled to a full-and-fair internal review with a written explanation of which specific concurrent treatment Humana considers duplicative and why. Submit within the deadline on your denial notice.
- External review: After the internal appeal, request IRO review within approximately four months of the final internal denial. IRO reviewers with hematology expertise can assess whether the duplicate-therapy characterization is clinically supportable.
- Expedited review: Appropriate if your current disease burden creates urgent risk from delay. Request simultaneously with your standard appeal.
## Building a Strong Appeal
### Documentation to Gather
1. Mechanistic distinction statement: A letter from your hematologist or treating specialist explaining, in clinical terms, that Casgevy's mechanism of action (genomic editing) is not replicated by any currently covered treatment, and that the two treatments cannot be considered interchangeable. 2. Current regimen documentation: A complete list of current treatments with their mechanisms, purposes, and the clinical rationale for each — making clear that none addresses the same therapeutic pathway as Casgevy. 3. Disease severity and burden documentation: Current and longitudinal records of disease activity, hospitalization history, transfusion history, pain crisis frequency, and organ involvement. This establishes that the need for a curative-intent therapy is distinct from managing acute manifestations. 4. Humana's duplicate-therapy policy: Obtain the exact policy language defining what constitutes a duplicate. Apply that definition to Casgevy's mechanism and the current regimen. 5. Specialist and guideline support: A reference to the applicable professional society (e.g., American Society of Hematology) recognizing Casgevy as a distinct therapeutic category, not a substitute for existing agents.
### Criteria-Mapping Structure
Identify the specific concurrent treatment Humana cited as the duplicate. For each element of Humana's duplicate-therapy definition, provide a one-sentence response: either the definition element does not apply (with clinical explanation) or the evidence shows the treatments serve distinct functions. This rebuttal-style mapping is the most effective format for this denial type.
## Key Message to Your Treating Specialist
A gene-editing therapy does not become a duplicate of a small-molecule or transfusion-support regimen simply because both treat the same underlying diagnosis. The appeal should emphasize that Casgevy is curative in intent and mechanistically unique, and that no currently covered treatment addresses the same therapeutic goal. Your specialist's letter should make this distinction explicit, citing the applicable hematology guideline organization's classification of available therapies.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →